| Cash Flow | 2025-06-30 |
|---|---|
| Net loss | -23,169 |
| Non-cash lease expense | 82 |
| Prepaid expenses | 45 |
| Employee advances | 0 |
| Operating lease liabilities | -87 |
| Lease receivables | 0 |
| Customer deposits | 0 |
| Accounts receivable | 0 |
| Accounts payable and accrued expenses | 5,638 |
| Impairment of long-term assets | 0 |
| Gain on settlement of debt | 196 |
| Depreciation and amortization | 577 |
| Stock based compensation | 7,444 |
| Unbilled revenue | 13 |
| Sales tax receivable | -3 |
| Common stock issued for services rendered | -7,244 |
| Allowance for credit losses on accounts receivable | -109 |
| Net cash used in operating activities | -2,393 |
| Business acquisition, net of cash acquired | -366 |
| Net cash provided by investing activity | 366 |
| Proceeds from issuance of related party note payable | 0 |
| Sale of common stock and warrants | 818 |
| Proceeds from sale of common stock and warrants, net of issuance costs | 0 |
| Sale of common stock under at-the- market offering, net of transaction costs | 3,882 |
| Net cash provided by financing activities | 4,700 |
| Effect of exchange rate changes on cash and cash equivalents | 5 |
| Net increase in cash and cash equivalents | 2,678 |
BioSig Technologies, Inc. (BSGM)
BioSig Technologies, Inc. (BSGM)